Skip to main content
NOVAVAX INC logo

NOVAVAX INC — Investor Relations & Filings

Ticker · NVAX ISIN · US6700024010 LEI · 529900J4GJHPEPQ23205 US Manufacturing
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2020-06-19 Capital/Financing Update
Country US United States of America
Listing US NVAX

About NOVAVAX INC

https://www.novavax.com/?locale=US

Novavax Inc. is a biotechnology company that develops and commercializes vaccines to prevent serious infectious diseases. The company utilizes a proprietary, protein-based vaccine technology platform, which includes its novel Matrix-M™ adjuvant, to create its vaccine candidates. Its primary commercial product is a protein-based COVID-19 vaccine, Nuvaxovid™. Novavax's research and development pipeline is focused on addressing significant health needs, including influenza and a combination COVID-19-influenza vaccine. The company's strategy emphasizes advancing its pipeline assets and establishing strategic partnerships to maximize the global health impact of its technology.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a private placement of Series A Convertible Preferred Stock, details of the subscription agreement, unregistered sale of equity securities, amendments to articles of incorporation, and other related corporate actions. There are no financial statements or comprehensive financial data typical of annual or quarterly reports. The document is primarily an announcement of a capital raising transaction and related corporate governance actions. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is over 10,000 characters, indicating it is a full filing, not just a brief announcement or certification. Hence, the classification is CAP with high confidence.
2020-06-19 English
FORM 4 SUBMISSION
Director's Dealing
2020-06-18 English
FORM 3 SUBMISSION
Director's Dealing
2020-06-18 English
DEFA14A
Board/Management Information Classification · 95% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed with the SEC. It is titled as a 'SUPPLEMENT TO PROXY STATEMENT' for the 2020 Annual Meeting of Stockholders. The content details the appointment of a new director, David M. Mott, to the company's Board of Directors, including his background, qualifications, and stock ownership. There is no financial data or earnings information, nor is it an announcement of a report publication. The document focuses on board/management information, specifically a change in the company's board of directors. Therefore, the appropriate classification is 'MANG' (Board/Management Information). The document length (7271 characters) supports it being a substantive filing rather than a brief announcement. Confidence is high due to clear identification of director appointment and proxy statement supplement context.
2020-06-18 English
FORM 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 14, 2020, for Novavax, Inc. The key content is the appointment of a new director, David M. Mott, to the company's Board of Directors, including details about his term, committee assignment, compensation, stock option award, and indemnification agreement. The document also references a press release about the appointment. There are no financial statements or earnings data presented. The primary focus is on a change in the company's board of directors. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 5811 characters, which is sufficient to be a full filing rather than a brief announcement. Therefore, the appropriate classification is MANG with high confidence.
2020-06-18 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content describes the entry into a material definitive agreement with the U.S. Department of Defense for funding related to a vaccine candidate. This type of filing is typically used to disclose significant events or agreements that are material to the company but are not periodic financial reports. The document does not contain financial statements or detailed financial analysis, nor is it an earnings release or annual report. It is a regulatory announcement of a material contract. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-06-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.